使用机器学习模型在慢性乙型肝炎患者中个性化选择抗病毒药物:一项跨国研究
这项跨国研究纳入13970例慢性乙型肝炎患者,建立并验证机器学习模型PLAN-S预测恩替卡韦或富马酸替诺福韦二吡呋酯治疗期间的个体化肝细胞癌风险。模型在各队列的c-index为0.67至0.78。在TDF优效组中,TDF与ETV相比肝细胞癌风险显著更低(HR=0.60-0.73,均P<0.05);在TDF非优效组中两药无显著差异(HR=1.16-1.29,均P>0.1)。
要点
- PLAN-S模型基于8个变量预测ETV或TDF治疗期间的个体化肝细胞癌风险,各队列c-index为0.67至0.78。
- TDF优效组在衍生队列、韩国验证队列及香港-台湾验证队列中分别占65.3%、63.5%和76.4%。
- TDF优效组中TDF较ETV的肝细胞癌风险显著更低(HR=0.60-0.73,均P<0.05);TDF非优效组两药无显著差异。
核心结论
- 考虑PLAN-S预测的个体肝细胞癌风险及TDF相关潜在毒性,TDF优效组和TDF非优效组可能分别推荐TDF和ETV治疗。
研究设计与样本
- 跨国研究,纳入13970例慢性乙型肝炎患者,建立衍生队列(n=6790)、韩国验证队列(n=4543)和香港-台湾验证队列(n=2637)。
- 当PLAN-S预测的ETV治疗下肝细胞癌风险大于TDF治疗下风险时,患者被归类为TDF优效组,其余为TDF非优效组。
主要发现
- PLAN-S模型使用8个变量衍生,各队列c-index为0.67至0.78。
- TDF优效组男性患者和肝硬化患者比例高于TDF非优效组。
- 衍生队列、韩国验证队列和香港-台湾验证队列中分别有65.3%、63.5%和76.4%的患者被归为TDF优效组。
- 各队列TDF优效组中,TDF与ETV相比肝细胞癌风险显著更低(HR=0.60-0.73,均P<0.05)。
- TDF非优效组中两药无显著差异(HR=1.16-1.29,均P>0.1)。
关键数值与推荐
- PLAN-S模型基于8个变量,各队列c-index为0.67至0.78。
- TDF优效组占比:衍生队列65.3%、韩国验证队列63.5%、香港-台湾验证队列76.4%。
- TDF优效组中TDF vs ETV的肝细胞癌风险HR=0.60-0.73(均P<0.05)。
- TDF非优效组中TDF vs ETV的肝细胞癌风险HR=1.16-1.29(均P>0.1)。
临床怎么用
- 考虑PLAN-S预测的个体肝细胞癌风险及TDF相关潜在毒性,作者认为TDF优效组和TDF非优效组可能分别推荐TDF和ETV治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Tenofovir disoproxil fumarate (TDF) is reportedly superior or at least comparable to entecavir (ETV) for the prevention of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B; however, it has distinct long-term renal and bone toxicities. This study aimed to develop and validate a machine learning model (designated as Prediction of Liver cancer using Artificial intelligence-driven model for Network-antiviral Selection for hepatitis B [PLAN-S]) to predict an individualized risk of HCC during ETV or TDF therapy. METHODS: This multinational study included 13,970 patients with chronic hepatitis B. The derivation (n = 6,790), Korean validation (n = 4,543), and Hong Kong-Taiwan validation cohorts (n = 2,637) were established. Patients were classified as the TDF-superior group when a PLAN-S-predicted HCC risk under ETV treatment is greater than under TDF treatment, and the others were defined as the TDF-nonsuperior group. RESULTS: The PLAN-S model was derived using 8 variables and generated a c-index between 0.67 and 0.78 for each cohort. The TDF-superior group included a higher proportion of male patients and patients with cirrhosis than the TDF-nonsuperior group. In the derivation, Korean validation, and Hong Kong-Taiwan validation cohorts, 65.3%, 63.5%, and 76.4% of patients were classified as the TDF-superior group, respectively. In the TDF-superior group of each cohort, TDF was associated with a significantly lower risk of HCC than ETV (hazard ratio = 0.60-0.73, all P < 0.05). In the TDF-nonsuperior group, however, there was no significant difference between the 2 drugs (hazard ratio = 1.16-1.29, all P > 0.1). DISCUSSION: Considering the individual HCC risk predicted by PLAN-S and the potential TDF-related toxicities, TDF and ETV treatment may be recommended for the TDF-superior and TDF-nonsuperior groups, respectively.
引用
- Hur MH, Park MK, Yip TC, et al. Personalized Antiviral Drug Selection in Patients With Chronic Hepatitis B Using a Machine Learning Model: A Multinational Study. Am J Gastroenterol. 2023. PMID: 36881437. doi:10.14309/ajg.0000000000002234
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。